Remimazolam during cardiopulmonary bypass

Evaluation of dose of remimazolam during cardiopulmonary bypass

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1011230015

Enrollment

Registered

2023-07-05

Start date

2023-07-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiocascular surgery

Interventions

Administration of remimazolam at different concentrations during cardiopulmonary bypass

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who receive cardiovascular surgery under cardiopulmonary bypass with mild hypothermia

Exclusion criteria

Exclusion criteria: Refusal to participate Emergent case Allergy against remimazolam Acute angle closure glaucoma Myasthenia gravis Hepatic failure (Child Pugh equal to or more than 2) Renal failure (sCre equal to or more than 2 mg/dL) Obesity (BMI equal to or more than 35 kg/m2) Deep hypothermic circulatory arrest Patients who are considered to be inappropriate to participate to the study

Design outcomes

Primary

Measure	Time frame
Concentration of free remimazolam	—

Secondary

Measure	Time frame
Concentration of total remimazolam, protein binding ratio of remimazolam, concentration of a metabolite of remimazolam (CNS7054), concentration of albumin, blood gas analysis, hemodynamics, BIS value, body temperature, time of blood sampling patients characteristics, surgery type, duration of anesthesia, duration of aortic clamp, duration of cardiopulmonary bypass, amount of fluid, dose of vasoactive agents, dose of anesthetics, amount of blood products, bleeding, urine output	—

Measure

Time frame

Concentration of total remimazolam, protein binding ratio of remimazolam, concentration of a metabolite of remimazolam (CNS7054), concentration of albumin, blood gas analysis, hemodynamics, BIS value, body temperature, time of blood sampling patients characteristics, surgery type, duration of anesthesia, duration of aortic clamp, duration of cardiopulmonary bypass, amount of fluid, dose of vasoactive agents, dose of anesthetics, amount of blood products, bleeding, urine output

—

Contacts

Public ContactYusuke Yoshikawa

Sapporo Medical University

y.yoshikawa@sapmed.ac.jp+81-11-688-9663

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026